Sysmex Corp (SSMXF)
19.32
0.00 (0.00%)
USD |
OTCM |
Dec 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.05B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 7.82% |
| Valuation | |
| PE Ratio | 34.53 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.762 |
| Price to Book Value | 3.902 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0996 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0662 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 66.67% |
Profile
| Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas. |
| URL | http://www.sysmex.co.jp |
| Investor Relations URL | https://www.sysmex.co.jp/en/ir/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |
Ratings
Profile
| Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas. |
| URL | http://www.sysmex.co.jp |
| Investor Relations URL | https://www.sysmex.co.jp/en/ir/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |